cagrisema phase 3 results 2025 semaglutide cagrilintide obesity Novo Nordisk A/S: Data på i fase (REDEFINE) Novo's Phase 3 CagriSema results

While AP-3 has been identified as an adaptor protein that is associated with BDNF-containing secretory granules, to date, it is not known if other adaptor proteins are associated with BDNF-containing granules

The confusion comes from both being discussed in longevity medicine, not from any real similarity between them

All the significance analysis was done using Statistica 8.0 software, using one-way ANOVA or two-tailed heteroscedastic Students t -test

This may serve to enhance its interaction with CPE or sortilin, further promoting the preferential sorting of BDNF into the RSP

Sources Novo Nordisks next-gen obesity drug CagriSema had investors excited

Preclinical data shows activity over 48 weeks in animal models